leadf
logo-loader
viewTarget Corporation
(
NYSE:TGT
)

Target Corp, Sorl Auto Parts, Tyson Foods and more - PRE-MARKET

A look at pre-market deals in New York ahead of the bell

1510752315_Target_187188074.jpg
Target Corp was in focus before the bell in New York

Wall Street futures point to a lower open and following that trend in pre-market was discount chain Target Corp (NYSE:TGT) as it posted third quarter earnings.

Shares dropped not far off 3.4% before the bell to US$60.09 despite reporting better-than-expected numbers.

The Minneapolis-based firm posted earnings per share (EPS) of US$0.91, which was US$0.05 better than the Wall Street consensus estimate of US$0.86 and toward the high end of the company’s own guidance.

 

Revenues rose 1.4% from last year to US$16.67 billion, compared with analysts’ view for US$16.61 billion.

 

Elsewhere, Sorl Auto Parts Inc (NASDAQ:SORL) shot up over 44.5% to US$8.66 after it reported strong results for its third quarter and raised its full year 2017 outlook.

Third quarter EPS (earnings per share)  was 44 cents, up from 17 cents in the same quarter of last year.

Also in the news in New York, Dicks Sporting Goods Inc (NYSE:DKS) was up 2.42% to US$ 26.21 before the bell after  broker heavyweight JP Morgan upgraded the shares to 'overweight' from 'neutral'.

Tyson Foods Inc (NYSE:TSN) shares gained 0.18% to US$76.21 in pre-market deals after it added 0.62% to US$76.07.

Quick facts: Target Corporation

Follow
NYSE:TGT

Price: 246.67 USD

Market Cap: $120.38 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

BioVaxys preps for Phase 1 study as vaccine manufacturing partner reaches...

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine. Kovan says the Lyon,...

1 day, 11 hours ago

2 min read